

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/833,196

DATE: 05/21/2001  
TIME: 12:14:40

Input Set : N:\Crf3\04272001\I833196.raw  
Output Set: N:\CRF3\05212001\I833196.raw

ENTERED

1 <110> APPLICANT: Abbott Laboratories  
2 Henkin, Jack  
3 Haviv, Fortuna  
4 Bradley, Michael F.  
5 Kalvin, Douglas M.  
6 Schneider, Andrew J.  
7 <120> TITLE OF INVENTION: PEPTIDE ANTIANGIOGENIC DRUGS  
8 <130> FILE REFERENCE: 6356.US.P4  
9 <140> CURRENT APPLICATION NUMBER: US/09/833,196  
10 <141> CURRENT FILING DATE: 2001-04-11  
11 <150> PRIOR APPLICATION NUMBER: US 09/316,888  
12 <151> PRIOR FILING DATE: 1999-05-21  
13 <150> PRIOR APPLICATION NUMBER: US 60/126,546  
14 <151> PRIOR FILING DATE: 1999-03-26  
15 <150> PRIOR APPLICATION NUMBER: US 60/086,536  
16 <151> PRIOR FILING DATE: 1998-05-22  
17 <160> NUMBER OF SEQ ID NOS: 6  
18 <170> SOFTWARE: FastSEQ for Windows Version 4.0  
20 <210> SEQ ID NO: 1  
21 <211> LENGTH: 10  
22 <212> TYPE: PRT  
23 <213> ORGANISM: Artificial Sequence  
24 <220> FEATURE:  
25 <223> OTHER INFORMATION: Antiangiogenetic Peptide  
26 <221> NAME/KEY: VARIANT  
27 <222> LOCATION: (1)...(1)  
28 <223> OTHER INFORMATION: Xaa = Ala, Asn, Cit, Gln, Glu, NetGly, Met,  
29 N-methylalanyl, Pro, pyro-Glu, Sar, Ser, or Thr at  
30 position 1  
31 <221> NAME/KEY: VARIANT  
32 <222> LOCATION: (2)...(2)  
33 <223> OTHER INFORMATION: Xaa = Ala, Asn, Asp, Gln, Glu, Leu, Met, Phe, Pro,  
34 or Ser at position 2  
35 <221> NAME/KEY: VARIANT  
36 <222> LOCATION: (3)...(3)  
37 <223> OTHER INFORMATION: Xaa = Ala, Asn, Cit, Cha, Chg, Gln, Glu, Gly, Ile,  
38 Leu, Met, Nva, Phe, Ser, tButylgly, Thr, Val, Pen,  
39 or Cys at position 3  
40 <221> NAME/KEY: VARIANT  
41 <222> LOCATION: (4)...(4)  
42 <223> OTHER INFORMATION: Xaa = alloIle, Gly, Ile, Pro, or dehydroleu at  
43 position 4  
44 <221> NAME/KEY: VARIANT  
45 <222> LOCATION: (5)...(5)  
46 <223> OTHER INFORMATION: Xaa = Ala, 3-Pal, 1-Nal, 2-Nal, allo-threonyl,  
47 allylgly, Gln, Gly, His, Hser, Ile, Lys(Ac), Met,  
48 Nva, Octylgly, Orn, Phe(4-CH2OH), Pro, Ser, Thr,

BEST AVAILABLE COPY

RAW SEQUENCE LISTING  
 PATENT APPLICATION: US/09/833,196  
 DATE: 05/21/2001  
 TIME: 12:14:40

Input Set: N:\Crf3\04272001\I833196.raw  
 Output Set: N:\CRF3\05212001\I833196.raw

```

49      Trp, Tyr, Pen, or Cys at position 5
50 <221> NAME/KEY: VARIANT
51 <222> LOCATION: (6)...(6)
52 <223> OTHER INFORMATION: Xaa = Ala, 1-Nal, 2-Nal, 3-Pal, Abu, allylgly,
53      Arg, Asn, Asp, Cit, Cha, Gln, Glu, Gly, His,
54      Homocala, Hle, Hser, Ile, Leu, Lys(Ac), Lys(Isp),
55      at position 6
56 <221> NAME/KEY: VARIANT
57 <222> LOCATION: (6)...(6)
58 <223> OTHER INFORMATION: 6 Cont'd:
59      Xaa = Met(O2), Met(O), Met, Nor, Nva, Octygly,
60      Phe, Phe(4-CONH2), Propargylgly, Ser, Thr, Trp,
61      Tyr, Val, Pen, or Cys at position 6
62 <221> NAME/KEY: VARIANT
63 <222> LOCATION: (7)...(7)
64 <223> OTHER INFORMATION: Xaa = Ala, Allylgly, Asn, Cit, Chg, Gln, Gly,
65      Hser, Ile, allole, Leu, Lys(Ac), Met, 1-Nal,
66      2-Nal, Nva, Phe, Pro, Ser, tButylgly, Trp, Tyr,
67      Val, Pen, or Cys at position 7
68 <221> NAME/KEY: VARIANT
69 <222> LOCATION: (8)...(8)
70 <223> OTHER INFORMATION: Xaa = Aminopyrimidinobutanoyl, Ala(3-guanidino),
71      Ala(3-pyrrolidinylamidino), Ala[4-Pip(N-amidino)],
72      Arg, arginyl(NGNG'diethyl), Cit, Cha(4-Nisp),
73      Gly[4-pip(N-amido)], at position 8
74 <221> NAME/KEY: VARIANT
75 <222> LOCATION: (8)...(8)
76 <223> OTHER INFORMATION: 8 Cont'd:
77      Xaa = His, Harg, Lys, Lys(Ile), Lys(Nic), Norarg,
78      Orn(Isp), Orn(Nic), Orn(2-imidazo),
79      Phe(4-CH2NHisp), Phe(4-guanidino), or Phe(4-Nisp)
W--> 80      at position 8
81 <221> NAME/KEY: VARIANT
82 <222> LOCATION: (9)...(9)
83 <223> OTHER INFORMATION: Xaa = Abu, Aib, homoprolyl, hydroxyprolyl, Ile,
84      Leu, Phe, Pro, Ser, tButylgly, Tic, Thr, or Val at
85      position 9.
86 <221> NAME/KEY: VARIANT
87 <222> LOCATION: (10)...(10)
88 <223> OTHER INFORMATION: Xaa = azaglycylamide, glycylamide,
89      glycylethylamide, sarcosylamide, serylamide at
90      position 10
91 <400> SEQUENCE: 1
W--> 92      Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
93          1          5          10
95 <210> SEQ ID NO: 2
96 <211> LENGTH: 9
97 <212> TYPE: PRT
98 <213> ORGANISM: Artificial Sequence
  
```

BEST AVAILABLE COPY

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/833,196

DATE: 05/21/2001

TIME: 12:14:40

Input Set : N:\Crf3\04272001\I833196.raw

Output Set: N:\CRF3\05212001\I833196.raw

```

99 <220> FEATURE:
100 <223> OTHER INFORMATION: Antiangiogenetic peptide
101 <221> NAME/KEY: VARIANT
102 <222> LOCATION: (1)...(1)
103 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1
104 <221> NAME/KEY: VARIANT
105 <222> LOCATION: (6)...(6)
106 <223> OTHER INFORMATION: Xaa = norvaline at position 6
107 <400> SEQUENCE: 2
W--> 108      Xaa Gly Val Ile Thr Xaa Ile Arg Pro
109          1           5
111 <210> SEQ ID NO: 3
112 <211> LENGTH: 9
113 <212> TYPE: PRT
114 <213> ORGANISM: Artificial Sequence
115 <220> FEATURE:
116 <223> OTHER INFORMATION: Antiangiogenetic peptide
117 <221> NAME/KEY: VARIANT
118 <222> LOCATION: (1)...(1)
119 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1
120 <221> NAME/KEY: VARIANT
121 <222> LOCATION: (6)...(6)
122 <223> OTHER INFORMATION: Xaa = norvaline at position 6
123 <400> SEQUENCE: 3
W--> 124      Xaa Gly Val Gly Thr Xaa Ile Arg Pro
125          1           5
127 <210> SEQ ID NO: 4
128 <211> LENGTH: 9
129 <212> TYPE: PRT
130 <213> ORGANISM: Artificial Sequence
131 <220> FEATURE:
132 <223> OTHER INFORMATION: Antiangiogenetic peptide
133 <221> NAME/KEY: VARIANT
134 <222> LOCATION: (1)...(1)
135 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1
136 <221> NAME/KEY: VARIANT
137 <222> LOCATION: (4)...(4)
138 <223> OTHER INFORMATION: Xaa = allo-isoleucyl at position 4
139 <221> NAME/KEY: VARIANT
140 <222> LOCATION: (6)...(6)
141 <223> OTHER INFORMATION: Xaa = norvaline at position 6
142 <400> SEQUENCE: 4
W--> 143      Xaa Gly Val Xaa Thr Xaa Ile Arg Pro
144          1           5
146 <210> SEQ ID NO: 5
147 <211> LENGTH: 9
148 <212> TYPE: PRT
149 <213> ORGANISM: Artificial Sequence
150 <220> FEATURE:

```

REST AVAILABLE COPY

## RAW SEQUENCE LISTING

DATE: 05/21/2001

PATENT APPLICATION: US/09/833,196

TIME: 12:14:40

Input Set : N:\Crf3\04272001\I833196.raw

Output Set: N:\CRF3\05212001\I833196.raw

```

151 <223> OTHER INFORMATION: Antiangiogenetic peptide
152 <221> NAME/KEY: VARIANT
153 <222> LOCATION: (1)...(1)
154 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1
155 <221> NAME/KEY: VARIANT
156 <222> LOCATION: (4)...(4)
157 <223> OTHER INFORMATION: Xaa = dehydroleucyl at position 4
158 <221> NAME/KEY: VARIANT
159 <222> LOCATION: (6)...(6)
160 <223> OTHER INFORMATION: Xaa = norvaline at position 6
161 <400> SEQUENCE: 5
W--> 162 Xaa Gly Val Xaa Thr Xaa Ile Arg Pro
163      1          5
165 <210> SEQ ID NO: 6
166 <211> LENGTH: 11
167 <212> TYPE: PRT
168 <213> ORGANISM: Artificial Sequence
169 <220> FEATURE:
170 <223> OTHER INFORMATION: Antiangiogenetic Peptide
171 <221> NAME/KEY: VARIANT
172 <222> LOCATION: (1)...(1)
173 <223> OTHER INFORMATION: Xaa = R-(CH2)n-C(O)- where R is N-acetylamino at
174 position 1
175 <221> NAME/KEY: VARIANT
176 <222> LOCATION: (2)...(2)
177 <223> OTHER INFORMATION: Xaa = Sar at position 2
178 <221> NAME/KEY: VARIANT
179 <222> LOCATION: (5)...(5)
180 <223> OTHER INFORMATION: Xaa = AlloIle, dehydroleu, Gly, Ile or Pro at
181 position 5
182 <221> NAME/KEY: VARIANT
183 <222> LOCATION: (6)...(6)
184 <223> OTHER INFORMATION: Xaa = Ala, 3-Pal, 1-Nal, 2-Nal, allo-threonyl,
185 allylgly, Gln, Gly, His, Hser, Ile, Lys(Ac), Met,
186 Nva, Octylgly, Orn, Phe(3-CH2OH), Pro, Ser, Thr,
187 Trp, Tyr, Pen or Cys at position 6
188 <221> NAME/KEY: VARIANT
189 <222> LOCATION: (7)...(7)
190 <223> OTHER INFORMATION: Xaa = Ala, 1-Nal, 2-Nal, 3-Pal, Abu, allylgly,
191 Arg, Asn, Asp, Cit, Cha, Gln, Glu, Gly, His,
192 Homoala, Hle, Hser, Ile, Leu, Lys(Ac), Lys(Isp),
193 at position 7
194 <221> NAME/KEY: VARIANT
195 <222> LOCATION: (7)...(7)
196 <223> OTHER INFORMATION: 7 Con'td:
197 Xaa = Met(O2), Met(O), Met, Nor, Nva, Octylgly,
198 Phe, Phe(4-CONH2), Propargylgly, Ser, Thr, Trp,
199 Tyr, Val, Pen, or Cys at position 7
200 <221> NAME/KEY: VARIANT

```

BEST AVAILABLE COPY

## RAW SEQUENCE LISTING

DATE: 05/21/2001

PATENT APPLICATION: US/09/833,196

TIME: 12:14:40

Input Set : N:\Crf3\04272001\I833196.raw

Output Set: N:\CRF3\05212001\I833196.raw

201 <222> LOCATION: (11)...(11)  
202 <223> OTHER INFORMATION: Xaa = Azaglycylamide, glycylamide,  
203 glycylethylamide, sarcosylamide, serylamide at  
204 position 11  
205 <400> SEQUENCE: 6  
W--> 206 Xaa Xaa Gly Val Xaa Xaa Xaa Ile Arg Pro Xaa  
207 1 5 10

BEST AVAILABLE COPY

## VERIFICATION SUMMARY

PATENT APPLICATION: US/09/833,196

DATE: 05/21/2001

TIME: 12:14:41

Input Set : N:\Crf3\04272001\I833196.raw

Output Set: N:\CRF3\05212001\I833196.raw

L:80 M:259 W: Allowed number of lines exceeded, &lt;223&gt; Other Information:

L:92 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1

L:108 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2

L:124 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3

L:143 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4

L:162 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5

L:206 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6

BEST AVAILABLE COPY